Arcus Biosciences, Inc.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Arcus Biosciences
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2026 Date: Monday, March 9th, 2026 Location: Miami, FL Format: Fireside chat & 1x1 meetings Time: 11:20 a.m. ET Barclays 28th...
Boston Herald
Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L)...
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Business Wire - 2 minutes ago Press Release All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Arcus Biosciences, Inc.
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
Arcus Biosciences (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter and year ended December 31st, 2025.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Recent Quotes View Full List My Watchlist Create Watchlist Indicators Industrial Estimate Composite Estimate 500 Stocks Estimate Gold Crude Oil Markets Stocks ETFs Tools Markets: Overview News Currencies International Treasuries By: Arcus Biosciences via Business Wire January 07, 2026 at 16:05 PM EST Arcus’s highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal...
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Business Wire - 14 minutes ago Press Release All information and data in this article is solely for informational purposes.
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
Business Wire - 11 minutes ago Press Release All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire - 3 minutes ago Press Release All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Arcus Biosciences, Inc.
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Business Wire - 5 minutes ago Press Release All information and data in this article is solely for informational purposes.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25 per share.
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Business Wire - 8 minutes ago Press Release All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Arcus Biosciences, Inc.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer Multiple readouts from the ARC-20 study of casdatifan are expected in 2026, including additional analyses of the late-line monotherapy cohorts early in 2026, followed by more mature data from the casdatifan plus cabozantinib cohort in mid-2026 and initial data from the...
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE: RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on a 2017 option and license agreement between Taiho and Arcus.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study | Salt Lake City News
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing development of domvanalimab plus zimberelimab and chemotherapy in the Phase 3 STAR-221 study in the same patient population Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ARC-20 study in late-line metastatic kidney cancer, relative to published data from studies with the only marketed HIF-2a inhibitor Median progression-free survival (mPFS) was 12.2 months, and 18-month landmark PFS was 43% in the pooled analysis of all four monotherapy cohorts Confirmed overall response rate (ORR) was 35%, with two additional responses pending...
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire - 4 minutes ago Columnist All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Contributor Content This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site.
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
Arcus Biosciences (NYSE: RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginning at 10:00 AM ET, in New York City. The event will highlight new data for Arcus’s HIF-2a inhibitor casdatifan from the monotherapy cohorts of the Phase 1b ARC-20 trial in late-line clear cell renal cell carcinoma (ccRCC).
Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP
Immune checkpoint inhibitors (ICIs) such as anti-CTLA-4 and anti-PD-(L)1 have revolutionized cancer treatment, providing proof that pharmacological intervention can enhance the body’s own tumor control. However, large successes for these agents are limited to “hot tumors,” tumors that have an active immune component where checkpoint inhibition can reinvigorate a subpar immune response.
Arcus Biosciences To Participate In Three Upcoming Investor Conferences
Business Wire - 4 minutes ago Columnist All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Contributor Content This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site.
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Indicators By: Arcus Biosciences via Business Wire August 06, 2025 at 16:05 PM EDT PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have been initiated Data from ARC-20 evaluating casdatifan + cabozantinib in IO-experienced ccRCC demonstrated that nearly half of patients had a confirmed response to the...
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire - 4 minutes ago Columnist All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Contributor Content This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site.
Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer, is expected to be fully enrolled by the end of this year. Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc.
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response | Financial News | myMotherLode.com
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Arcus
Contact Arcus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack